© PHARMED CANADA

Program

7:45-8:30

REGISTRATION & Networking Breakfast

​8:30 - 8:35

 Opening words

 Perry Niro, President, Pharmed Canada  & Anie Perrault, Executive Director, BIOQuébec

 

8:35 - 9:30

Stock Exchange & Public Market: is the window opening ?

 

Moderator: Lolita Guerrera, Associate Vice-Presidente, RBC Royal Bank

 

Market Review in Life Sciences

Douglas Miehm, Managing Director, Global Research, Healthcare, RBC Capital Markets, Toronto

My $ 100 M IPO on NASDAQ

Michael Singer, CFO, CLÉMENTIA

9:30 - 10:15

MEDTECH & Artificial Intelligence

Investors & Entrepreneurs points of view of Artificial Intelligence is impacting Life Sciences

Moderator: Benoit Larose, Vice-President Quebec, MEDEC

  • Katherine Parra Moreno, VP Medtech/Digital Health, Venture Capital, Epic Capital Management

  • Alexandre Le Bouthiller, President & Founder, IMAGIA Cybernetics

  • Louise Beauchesne, Executive Regional Director, Quebec & Atlantic, IBM Canada

​10:15 - 10:30

Networking Break

10:30 - 12:00

 Dragon Den's Start-Up Pitch

New this year, four companies will be invited to make a 5 minutes pitch to our panels of investors. The panelists will be invited to comment on the presentation, give some advice and share some insight.

 

Following these presentations, participants will be invited to vote on the best presentation. 

Moderated by Perry Niro, President of Pharma Canada and Tuba Yamac, Senior Patent Agent at BCF LLP.

 

The winner will receive a package of professional services from BCF. 

 

The participants for this year's Dragon Den are

  1. Simon Sanscartier, CFO, MYOVUE

  2. Bernard Fortier, CEO, Tetra Bio-Pharma

  3. Véronique Bougie, CEO, Corbin Therapeutics

  4. Francois-Thomas Michaud, CEO, Feldan Therapeutics

This year's Dragons are:

ttt
  1. Michael Lincoln, Chief Financial and Business Officer, Accel-Rx Health Sciences Fund (Vancouver)

  2. Jean-François Pariseau,  Partner, Healthcare Fund, BDC Capital (Montreal)

  3. Nicola Urbani, Investment Director, Emerillon Capital (Montreal)

  4. Paulina S. Hill, Principal, Polaris Partners (Boston)

  5. Lidija Marusic, Investment Manager, Innovacorp (Halifax)

12:00 - 13:30
 
Luncheon Conference
Moderator: Anie Perrault,
Executive Director, BIOQuébec
 

Ernst & Young 2017 Report

Staying the Course

  •  Lara Iob, CPA, Partner, EY Canada

  •  Yann Lavallée, Partner, EY Canada

13:30 - 15:00  

Co-Development & Alternatives Funding Opportunities

 

AstraZeneca's Open Innovation Program

The Open Innovation platform provides an open, collaborative approach to link AstraZeneca's expertise, unique research tools, optimised molecules, technologies and challenges with start-ups research capabilities and interests. Come learn how you can work together with AZ to accelerate the advancement of medical science and bring novel therapies to patients.

  • Pamela Hill, Associate director, Open Innovation Program Manager, AstraZeneca

 

CF Foundation Venture Philanthropy Model

Through its venture philanthropy model, the Cystic Fibrosis Foundation provides early stage funding to biotechnology and pharmaceutical companies to develop breakthrough drugs for adults and children with cystic fibrosis. Presentation on the model, and some ideas on how to extend it to other organizations.

  • John Wallenburg, Chief Scientific Officer, Cystic Fibrosis Canada

 

Business Tax Incentives for start-ups

Business tax incentives and government grants constitute a lucrative source of funding for start-up companies based in Quebec and Canada. As a Life Science start-up company, find out how to use Canadian and Quebec financial incentives and grants to allow you to grow your company, innovate and advance in your field!

  • Soraya Khouadri, Manager, SR&ED & BTI services, EY Canada

 

Legal & IP Start-Up Program

BCF is proud to contribute to the success of Quebec startups, as well as entrepreneurs that will become the leaders of tomorrow’s economy. With BCF Imagine, we are offering a complete range of legal services and business coaching, all the while keeping your specific needs in mind. Our objective is to assure that your business reaches its full potential. We will ensure that your technological business is protected and properly valued, so that you can focus on changing the world in your own way.

  • Me Brigitte Nepveu, Partner, Lawyer, & Andréanne Auger, Senior Patent Agent, BCF Business Law

​15:00

Closing & B2B Meetings